Daré Bioscience Performance degli utili passati
Criteri Il passato verificati 0/6
Daré Bioscience ha registrato una crescita degli utili a un tasso medio annuo di 22.3%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 9.1%. I ricavi sono stati in diminuzione a un tasso medio annuo di 11.3%.
Informazioni chiave
22.27%
Tasso di crescita degli utili
42.32%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 5.95% |
| Tasso di crescita dei ricavi | -11.30% |
| Rendimento del capitale proprio | -471.37% |
| Margine netto | -1,300.66% |
| Ultimo aggiornamento sugli utili | 31 Dec 2025 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Women’s Health Pipeline Risks Will Persist Yet Long Term Potential Will Eventually Emerge
Catalysts About Daré Bioscience Daré Bioscience develops women’s health products across sexual health, contraception, menopause, vaginal health and infectious disease, with a focus on differentiated formulations built around known compounds. What are the underlying business or industry changes driving this perspective?
Women’s Health Pipeline And Dual 503B Pathway Will Transform Long Term Earnings Potential
Catalysts About Daré Bioscience Daré Bioscience focuses on developing and commercializing women’s health products across sexual health, contraception and menopause. What are the underlying business or industry changes driving this perspective?
Women’s Health Platform And 503B Launches Will Reshape Long-Term Outlook
Catalysts About Daré Bioscience Daré Bioscience is a women's health company focused on developing and commercializing clinically supported products across sexual health, contraception, menopause and vaginal health. What are the underlying business or industry changes driving this perspective?We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms
Daré Bioscience (NASDAQ:DARE) is trading 6.5% higher after the company announced positive data from its Phase 1/2 clinical trial of investigational intravaginal ring, DARE-HRT1, to treat the vasomotor symptoms and genitourinary syndrome associated with menopause. The drug is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy regimen. The topline data from the study showed improvement in both vasomotor symptoms as well as vaginal symptoms of menopause. The primary objective or the main goal of the study was to demonstrate the safety, tolerability, and pharmacokinetics (PK) of two different dose combinations over 12 weeks of use. The company said the levels of estradiol released from both the lower and higher dose formulation of DARE-HRT1 evaluated in the study achieved statistically significant improvement. Menopausal symptoms, including hot flashes and night sweats, were reduced compared with baseline in both DARE-HRT1 dose groups. The topline PK data from the study will be available later in Q4.Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive
Daré Bioscience (NASDAQ:DARE) is trading 5.3% higher after the U.S. Food and Drug Administration approved its investigational device exemption (IDE) application to conduct an efficacy study of investigational hormone-free monthly intravaginal contraceptive, Ovaprene. The IDE approval will mean the FDA determined that the company provided sufficient data to support the initiation and conduct of the study. The submission included the results of the postcoital test clinical study of Ovaprene, in which the therapy prevented sperm from entering the cervical canal across all women and all cycles evaluated. The company is targeting mid-year 2023 to begin study recruitment.Dare Bioscience reports positive progress for cream for female sexual arousal disorder
Dare Bioscience (NASDAQ:DARE) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line data announcement in Q2 2023. Sildenafil is the active ingredient in Viagra, a pill approved for erectile dysfunction. Dare (DARE) noted that its sildenafil cream is designed to be applied to the vaginal tissue just prior to intercourse to increase blood flow directly to the tissue. Seeking Alpha Quant Rating views Dare (DARE) as a hold with high marks for growth and revisions.Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy
Women health firm Daré Bioscience (NASDAQ:DARE) announced an exclusive license agreement with clinical-stage biopharma firm Organon (NYSE:OGN) to commercialize Xaciato, DARE's treatment of bacterial vaginosis in patients 12 years of age and older. Under the agreement, Daré will receive a $10M upfront payment from Organon and is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. Xaciato will be commercially available in the U.S. in Q4, DARE said. The companies entered into the agreement on March 31.Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Diving Back Into Daré Bioscience Again
Today, we revisit women's health concern Daré Bioscience for the first time in nearly a year. This small cap concern just received its first FDA approval and is advancing other candidates in its pipeline. A full investment analysis follows in the paragraphs below.We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching
While Daré Bioscience, Inc. ( NASDAQ:DARE ) might not be the most widely known stock at the moment, it led the NASDAQCM...Ripartizione dei ricavi e delle spese
Come Daré Bioscience guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 1 | -13 | 9 | 6 |
| 30 Sep 25 | 0 | -17 | 9 | -6 |
| 30 Jun 25 | 0 | -19 | 9 | -5 |
| 31 Mar 25 | 0 | -2 | 9 | 0 |
| 31 Dec 24 | 0 | -4 | 9 | 14 |
| 30 Sep 24 | 2 | -4 | 10 | -7 |
| 30 Jun 24 | 3 | -7 | 11 | -3 |
| 31 Mar 24 | 3 | -29 | 11 | -5 |
| 31 Dec 23 | 3 | -30 | 12 | 0 |
| 30 Sep 23 | 1 | -41 | 12 | 1 |
| 30 Jun 23 | 0 | -40 | 12 | -2 |
| 31 Mar 23 | 10 | -31 | 12 | -1 |
| 31 Dec 22 | 10 | -31 | 11 | 0 |
| 30 Sep 22 | 10 | -25 | 10 | 24 |
| 30 Jun 22 | 10 | -30 | 10 | 30 |
| 31 Mar 22 | 0 | -40 | 9 | 31 |
| 31 Dec 21 | 0 | -39 | 8 | 31 |
| 30 Sep 21 | 0 | -38 | 8 | 30 |
| 30 Jun 21 | 0 | -33 | 7 | 26 |
| 31 Mar 21 | 0 | -30 | 7 | 24 |
| 31 Dec 20 | 0 | -27 | 7 | 21 |
| 30 Sep 20 | 0 | -23 | 6 | 17 |
| 30 Jun 20 | 0 | -19 | 6 | 12 |
| 31 Mar 20 | 0 | -16 | 6 | 9 |
| 31 Dec 19 | 0 | -15 | 5 | 9 |
| 30 Sep 19 | 0 | -14 | 5 | 8 |
| 30 Jun 19 | 0 | -13 | 5 | 8 |
| 31 Mar 19 | 0 | -12 | 5 | 7 |
| 31 Dec 18 | 0 | -17 | 5 | 6 |
| 30 Sep 18 | 0 | -23 | 4 | 5 |
| 30 Jun 18 | 0 | -22 | 4 | 4 |
| 31 Mar 18 | 0 | -19 | 3 | 2 |
| 31 Dec 17 | 0 | -12 | 2 | 1 |
| 30 Sep 17 | 0 | -3 | 2 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
Guadagni di qualità: DARE al momento non è redditizia.
Margine di profitto in crescita: DARE al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: DARE non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 22.3% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di DARE nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: DARE non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( -5% ).
Rendimento del capitale proprio
ROE elevato: DARE ha un Return on Equity negativo ( -471.37% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/14 06:39 |
| Prezzo dell'azione a fine giornata | 2026/05/14 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Daré Bioscience, Inc. è coperta da 5 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Douglas Tsao | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |